SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout
16 déc. 2020 14h56 HE
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Prevail Therapeutics Inc. (“Prevail”) (NASDAQ GS: PRVL) regarding possible breaches...
PREVAIL THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRVL and Encourages Investors to Contact the Firm
16 déc. 2020 12h37 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm
20 oct. 2020 19h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company...
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm
15 oct. 2020 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company...
Global Rheumatoid Arthritis Therapeutics Market; High adoption of disease-modifying antirheumatic drugs (DMARDs) will boost the market - PMI
25 juin 2020 10h35 HE
|
PMI
Covina, CA, June 25, 2020 (GLOBE NEWSWIRE) -- The global rheumatoid arthritis therapeutics market accounted for US$ 25.7 billion in 2019 and is estimated to be US$ 39.8 billion by 2029 and is...
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
23 janv. 2019 09h25 HE
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...
Endocrinologist & Researcher Dr. Dara P. Schuster Named CEO of T1D Exchange
22 juin 2018 08h00 HE
|
T1D Exchange
BOSTON, June 22, 2018 (GLOBE NEWSWIRE) -- T1D Exchange, a patient-centered research organization dedicated to accelerating therapies and improving care for people with type 1 diabetes (T1D), today...
CORRECTING and REPLACING – Protomer Technologies Takes Top Prize in 2018 Diabetes Innovation Challenge
22 mai 2018 10h10 HE
|
T1D Exchange
In a release issued under the same headline earlier today by T1D Exchange please note that in the third paragraph of the release the name of the Protomer Technologies Founder and CEO should by Alborz...
Protomer Technologies Takes Top Prize in 2018 Diabetes Innovation Challenge
22 mai 2018 07h00 HE
|
T1D Exchange
BOSTON, May 22, 2018 (GLOBE NEWSWIRE) -- Protomer Technologies of Pasadena, CA, will receive $50,000 in cash and up to $150,000 of in-kind support as the winner of the 2018 Diabetes Innovation...
PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer
21 mai 2018 09h20 HE
|
PharmaCyte Biotech
NEW YORK, NY, May 21, 2018 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application...